Discordant prostate specific antigen test results despite WHO assay standardization

Introduction: Total PSA (tPSA) and free PSA (fPSA) are the most commonly used biomarkers for early detection of prostate cancer. Despite standardization efforts, many available PSA assays may still produce discordant results. In the present study, we compared four PSA assays calibrated to the WHO standards 96/670 and 96/668 for tPSA and fPSA, respectively. Methods: Within the scope of the Prostate Cancer Early Detection Study Based on a ‘‘Baseline’’ PSA Value in Young Men (PROBASE), we tested tPSA and fPSA in serum samples from 50 patients in the four different PROBASE sites using four WHO-calibrated assays from Roche (Elecsys, Cobas), Beckman-Coulter (Access-II) and Siemens (ADVIA Centaur). The comparison was performed using the Passing–Bablok regression method. Results: Compared to Access, the median tPSA levels for Centaur, Elecsys, and Cobas were +3%, +11%–20%, and +17%–23%, respectively, while for median fPSA levels the differences for Centaur, Elecsys, and Cobas were +49%, +29%–31%, and +22%, respectively. Discussion: Despite all investigated assays being WHO-calibrated, the Elecsys and Cobas tPSA assays produced considerably higher results than the Access and Centaur assays. Differences in fPSA-recovery between all investigated assays were even more pronounced. When applying the tPSA cutoff of 3.1 μg/L recommended for WHO-calibrated assays, the use of higher calibrated assays may lead to unnecessary prostate biopsies. Conversely, if the historical threshold of 4 μg/L is applied when using WHO-calibrated assays, it could lead to falsely omitted prostate biopsies.

[1]  Thomas Streichert,et al.  Criteria for assigning laboratory measurands to models for analytical performance specifications defined in the 1st EFLM Strategic Conference , 2019 .

[2]  Sverre Sandberg,et al.  Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine , 2015, Clinical chemistry and laboratory medicine.

[3]  P. Bossuyt,et al.  Setting analytical performance specifications based on outcome studies – is it possible? , 2015, Clinical chemistry and laboratory medicine.

[4]  R. Molina,et al.  Variability of assay methods for total and free PSA after WHO standardization , 2014, Tumor Biology.

[5]  G. Kristiansen,et al.  Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial. , 2013, European urology.

[6]  B. Tombal,et al.  Prostate cancer screening: clinical impact of WHO calibration of Beckman Coulter Access® prostate-specific antigen assays , 2010, Clinical chemistry and laboratory medicine.

[7]  W. Catalona,et al.  20–25% Lower Concentrations of Total and Free Prostate-Specific Antigen (PSA) after Calibration of PSA Assays to the WHO Reference Materials – Analysis of 1098 Patients in Four Centers , 2009 .

[8]  M. Roobol,et al.  Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection. , 2008, Clinical chemistry.

[9]  C. Stephan,et al.  Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards , 2008, Clinical chemistry and laboratory medicine.

[10]  G. Vignati,et al.  Standardization of PSA Measures: A Reappraisal and an Experience with WHO Calibration of Beckman Coulter Access Hybritech Total and Free PSA , 2007 .

[11]  S. Loening,et al.  Different prostate‐specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies , 2007, BJU international.

[12]  R. Dittadi,et al.  Interchangeability and diagnostic accuracy of two assays for total and free prostate-specific antigen: two not always related items. , 2007, The International journal of biological markers.

[13]  M. Blankenstein,et al.  Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. , 2006, Clinical chemistry.

[14]  A. Semjonow,et al.  A New Modification of the Chiron ACS Assay for Total Prostate-Specific Antigen Achieves Equimolar Response Characteristics and Improves the Detection of Prostate Cancer , 2003, Clinical Chemistry and Laboratory Medicine.

[15]  A. Semjonow,et al.  The clinical impact of different assays for prostate specific antigen , 2000, BJU international.

[16]  D. Chan,et al.  WHO first international standards for prostate-specific antigen: the beginning of the end for assay discrepancies? , 2000, Clinical chemistry.

[17]  R. G. Das,et al.  Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10) , 2000, Clinical chemistry.

[18]  B. G. Blijenberg,et al.  New developments in the standardization of total prostate-specific antigen. , 1999, Clinical biochemistry.

[19]  B. G. Blijenberg,et al.  On the Standardization of Total Prostate-Specific Antigen: an Exercise with Two Reference Preparations , 1999, Clinical chemistry and laboratory medicine.

[20]  A W Partin,et al.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.

[21]  W. Catalona,et al.  Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. , 1998, The Journal of urology.

[22]  A W Partin,et al.  Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. , 1996, Urology.

[23]  A. Semjonow,et al.  Discordance of assay methods creates pitfalls for the interpretation of prostate‐specific antigen values , 1996, The Prostate. Supplement.

[24]  M. Brawer,et al.  Variation in measurement of prostate-specific antigen: importance of method and lot variability. , 1995, Clinical chemistry.

[25]  T. Stamey,et al.  Identity of PSA purified from seminal fluid by different methods: Comparison by amino acid analysis and assigned extinction coefficients , 1995, The Prostate.

[26]  H. Pahl,et al.  Methodological and clinical comparison of the ACS prostate-specific antigen assay and the Tandem-E prostate-specific antigen assay in prostate cancer. , 1995, Urology.

[27]  T. Stamey.  Second Stanford Conference on International Standardization of Prostate-Specific Antigen Immunoassays: September 1 and 2, 1994. , 1995, Urology.

[28]  U. Stenman,et al.  Standardization of PSA determinations. , 1995, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[29]  J. Richie,et al.  Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. , 1994, The Journal of urology.

[30]  Louis R Kavoussi,et al.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. , 1994, The Journal of urology.

[31]  H. C. Graves,et al.  Standardization of immunoassays for prostate‐specific antigen. A problem of prostate‐specific antigen complexation or a problem of assay design? , 1993, Cancer.

[32]  B. Bluestein,et al.  Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays. , 1993, Clinical chemistry.

[33]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[34]  T. Stamey,et al.  Comparison of a polyclonal and monoclonal immunoassay for PSA: need for an international antigen standard. , 1990, The Journal of urology.

[35]  G. Sensabaugh,et al.  Seminal plasma protein p30: simplified purification and evidence for identity with prostate specific antigen. , 1990, The Journal of urology.

[36]  E. Cooper.  Clinical Utility of Prostate Specific Antigen in the Management of Prostatic Cancer , 1988 .

[37]  W. Bablok,et al.  A New Biometrical Procedure for Testing the Equality of Measurements from Two Different Analytical Methods. Application of linear regression procedures for method comparison studies in Clinical Chemistry, Part I , 1983, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

[38]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.